PDCD1 and neoplasm: Current immune checkpoint inhibitor (ICI) therapy works by blocking the interaction between the programmed death-ligand 1 (PD-L1) on tumor cells and the programmed cell death protein 1 (PD-1) on T cells, thereby allowing the T cells to kill the tumor cells.